Literature DB >> 6393862

Pharmacokinetics of ceftazidime in newborn infants.

G H McCracken, N Threlkeld, M L Thomas.   

Abstract

Doses of 50 mg of ceftazidime per kg were administered intravenously to 29 newborn infants every 8 or 12 h for 3 to 5 days. Mean peak concentrations in plasma ranged from 102 to 124 micrograms/ml. Mean elimination half-life values ranged from 2.9 to 6.7 h and varied inversely with gestational age and plasma clearances. Peak and trough plasma bactericidal titers against an Escherichia coli and a group B streptococcus strain were at least 1:16 and 1:32, respectively.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6393862      PMCID: PMC179969          DOI: 10.1128/AAC.26.4.583

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  4 in total

1.  Serial dilution antibiotic sensitivity testing with the microtitrator system.

Authors:  J H Marymont; R M Wentz
Journal:  Am J Clin Pathol       Date:  1966-05       Impact factor: 2.493

2.  Comparison of the concentrations of ceftazidime in the serum of newborn infants after intravenous and intramuscular administration.

Authors:  A Boccazzi; M Rizzo; M L Caccamo; B M Assael
Journal:  Antimicrob Agents Chemother       Date:  1983-12       Impact factor: 5.191

3.  Ro 13-9904 and GR 20263, two new cephalosporins with broad-spectrum activity: an in vitro comparison with other beta-lactam antibiotics.

Authors:  A M Clarke; S J Zemcov
Journal:  J Antimicrob Chemother       Date:  1981-05       Impact factor: 5.790

4.  GR-20263: a new aminothiazolyl cephalosporin with high activity against Pseudomonas and Enterobacteriaceae.

Authors:  L Verbist; J Verhaegen
Journal:  Antimicrob Agents Chemother       Date:  1980-05       Impact factor: 5.191

  4 in total
  9 in total

Review 1.  [Ceftazidime in the treatment of pediatric infections--a review].

Authors:  D Adam; R Tolxdorff-Neutzling
Journal:  Infection       Date:  1987       Impact factor: 3.553

Review 2.  Clinical pharmacokinetics of antibacterial drugs in neonates.

Authors:  C M Paap; M C Nahata
Journal:  Clin Pharmacokinet       Date:  1990-10       Impact factor: 6.447

3.  Ceftazidime pharmacokinetics in preterm infants: effect of postnatal age and postnatal exposure to indomethacin.

Authors:  J N van den Anker; W C Hop; R C Schoemaker; B J van der Heijden; H J Neijens; R de Groot
Journal:  Br J Clin Pharmacol       Date:  1995-11       Impact factor: 4.335

Review 4.  Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics.

Authors:  J Singh; B Burr; D Stringham; A Arrieta
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

5.  Once-daily versus twice-daily administration of ceftazidime in the preterm infant.

Authors:  J N van den Anker; R C Schoemaker; B J van der Heijden; H M Broerse; H J Neijens; R de Groot
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

6.  Comparison of serum concentrations of ceftazidime and tobramycin in newborn infants.

Authors:  I Tessin; K Thiringer; B Trollfors; J E Brorson
Journal:  Eur J Pediatr       Date:  1988-05       Impact factor: 3.183

Review 7.  Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Richards; R N Brogden
Journal:  Drugs       Date:  1985-02       Impact factor: 9.546

Review 8.  Pharmacokinetics of cephalosporins in the neonate: a review.

Authors:  Gian Maria Pacifici
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

Review 9.  Clinical Pharmacokinetics of Penicillins, Cephalosporins and Aminoglycosides in the Neonate: A Review.

Authors:  Gian Maria Pacifici
Journal:  Pharmaceuticals (Basel)       Date:  2010-08-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.